D. Gustafsson

发表

Noninvasive measurement of diameter changes in the distal abdominal aorta in man.

D Bergqvist, T Länne, B. Sonesson, 1992, Ultrasound in medicine & biology.

Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.

K. Hansson, O. Fjellström, D. Gustafsson, 2014, Bioorganic & medicinal chemistry letters.

Factor V Leiden (G1691A) and Prothrombin Gene G20210A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery

T. Lindahl, B. Eriksson, C. Andersson, 2002, Thrombosis and Haemostasis.

A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.

D. Gustafsson, M. Elg, 2006, Thrombosis research.

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

B. Eriksson, L. Welin, L. Frison, 2002, The Lancet.

Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor

L. Johansson, U. Eriksson, L. Frison, 2003, Clinical pharmacokinetics.

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

L. Johansson, U. Eriksson, D. Gustafsson, 2003, Clinical pharmacokinetics.

Plasminogen binding inhibitors demonstrate unwanted activities on GABAA and glycine receptors in human iPSC derived neurons

T. Fex, D. Gustafsson, Anders Lundin, 2018, Neuroscience Letters.

Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B

K. Hansson, E. Berntorp, L. Frison, 2015, Journal of thrombosis and haemostasis : JTH.

A serendipitously identified novel small molecule procoagulant compound giving rise to a high-throughput screening assay based on human plasma.

J. Ulander, O. Fjellström, J. Deinum, 2013, Thrombosis research.

Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects

M. Wolzt, U. Eriksson, L. Frison, 2002, Thrombosis and Haemostasis.

The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats.

D. Gustafsson, M. Elg, A. Mikulski, 2001, Thrombosis research.

Superoxide dismutase and catalase do not improve recovery of regional myocardial contractile function when given at the time of reperfusion after reversible regional ischemia in anesthetized dogs

P. Sjöquist, J. Björkman, D. Gustafsson, 1991, Basic Research in Cardiology.

Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.

S. Carlsson, D. Gustafsson, M. Elg, 2001, Thrombosis research.

Discovery and Evaluation of Anti-Fibrinolytic Plasmin Inhibitors Derived from 5-(4-Piperidyl)isoxazol-3-ol (4-PIOL)

Thomas C. Schmidt, Thomas C Schmidt, D. Cosgrove, 2017, J. Chem. Inf. Model..

Creating Novel Activated Factor XI Inhibitors through Fragment Based Lead Generation and Structure Aided Drug Design

O. Fjellström, I. Nilsson, T. Olsson, 2015, PloS one.

Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.

W. Lindberg, A. Plowright, Yafeng Xue, 2014, ACS medicinal chemistry letters.

Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.

S. Carlsson, D. Gustafsson, M. Elg, 2001, Thrombosis research.

Factor V Leiden ( G 1691 A ) and Prothrombin Gene G 20210 A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery

T. Lindahl, B. Eriksson, C. Andersson, 2018 .

Oral direct thrombin inhibitors in clinical development

D. Gustafsson, 2003, Journal of internal medicine.

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.

U. Bredberg, K. Hoffmann, U. Eriksson, 2003, Drug metabolism and disposition: the biological fate of chemicals.

The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality

R. Unwin, D. Gustafsson, 2013, BMC Nephrology.

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r‐hirudin in a human ex vivo model of arterial thrombosis

J. Badimón, J. Osende, U. Eriksson, 2003, Journal of thrombosis and haemostasis : JTH.

A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I

S. Schulman, L. Welin, H. Eriksson, 2003, Journal of thrombosis and haemostasis : JTH.

Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes

S. Pehrsson, H. Sörensen, I. Nilsson, 1998, Thrombosis and Haemostasis.

Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.

J. Mehta, W. Nichols, T. Saldeen, 1998, Journal of cardiovascular pharmacology.

Central hemodynamic effects of adrenaline with special reference to beta 2-adrenergic influence on heart rate and cardiac afterload in anesthetized cats.

J. Björkman, D. Gustafsson, 1984, Acta physiologica Scandinavica.

Acute haemodynamic effects of felodipine, verapamil and hydralazine in the anaesthetized dog.

B. Ljung, J. Björkman, D. Gustafsson, 1991, Pharmacology & toxicology.

Microvascular mechanisms involved in calcium antagonist edema formation.

D. Gustafsson, 1987, Journal of cardiovascular pharmacology.

Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function

A. Sabirsh, Tomas Åkerud, S. Martinsson, 2020, The Journal of Biological Chemistry.

Exploration of efficacy and bleeding with combined phosphoinositide 3‐kinase β inhibition and aspirin in man

D. Gustafsson, F. Wågberg, T. Skärby, 2015, Journal of thrombosis and haemostasis : JTH.

Raised plasma concentrations of endothelin-1 and -3 in marmosets with acute aortic stenosis: no relation to the renin-angiotensin system.

T. Hedner, F. Fyhrquist, D. Gustafsson, 1992, Blood pressure.

Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis

H. Thorlacius, O. Braun, D. Gustafsson, 2013, Platelets.

Microvascular effects and oedema formation of felodipine in man.

T. Länne, J. Lundvall, P. Bjerkhoel, 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Effects of Calcium Antagonists on Myogenic and Neurogenic Control of Resistance and Capacitance Vessels in Cat Skeletal Muscle

P. Grände, P. Borgström, D. Gustafsson, 1988, Journal of cardiovascular pharmacology.

Characterization of a Small Molecule Inhibitor of Plasminogen Activator Inhibitor Type 1 That Accelerates the Transition into the Latent Conformation*

S. Geschwindner, T. Sjögren, O. Fjellström, 2012, The Journal of Biological Chemistry.

Effects of thiopental on resistance vessels in cat skeletal muscle

P. Grände, D. Gustafsson, L. Lindberg, 2005, Intensive Care Medicine.

Effects of noradrenaline and vasopressin analogues on resistance and capacitance vessels in the rat hindquarter preparation.

P. Melin, D. Gustafsson, M. Elg, 1990, Acta physiologica Scandinavica.

Microsphere analysis of beta 2-adrenergic control of resistance in different vascular areas after hemorrhage.

J. Lundvall, D. Gustafsson, L. Andersson, 1984, Acta physiologica Scandinavica.

beta 2-Adrenergic control of plasma volume in hemorrhage.

J. Lundvall, J. Hillman, D. Gustafsson, 1982, Acta physiologica Scandinavica.

The role of sympathetic activity in atherogenesis: effects of beta-blockade.

G. Hansson, K. Pettersson, J. Björkman, 1988, American heart journal.

Human target validation of phosphoinositide 3‐kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

B. Kull, O. Fjellström, T. Inghardt, 2012, Journal of thrombosis and haemostasis : JTH.

A new rat model of arterial thrombosis with a platelet‐rich head and an erythrocyte‐rich tail: thrombolysis experiments with specific thrombin inhibition

D. Gustafsson, A. Eriksson, S. Wikström, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I

B. Eriksson, U. Eriksson, L. Frison, 2002, Thrombosis and Haemostasis.

Effects of inogatran, a new low‐molecular‐weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time

D. Gustafsson, A. Teger‐Nilsson, M. Elg, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Discovery of AZD8165 – a clinical candidate from a novel series of neutral thrombin inhibitors

U. Bredberg, J. Bergman, S. Pehrsson, 2016 .

From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs.

Eric Therrien, Yafeng Xue, W. V. Otterlo, 2009, Bioorganic & medicinal chemistry letters.

In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor.

U. Eriksson, A C Teger-Nilsson, R Bylund, 1997, Thrombosis research.

A new oral anticoagulant: the 50-year challenge

Ingemar Nilsson, Ulf Bredberg, David Gustafsson, 2004, Nature Reviews Drug Discovery.

The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.

David Gustafsson, D. Gustafsson, Margareta Elg, 2003, Thrombosis research.

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.

A Abrahamsson, U Bredberg, U. Bredberg, 2001, Thrombosis research.

The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis

J. Deinum, J Deinum, D Gustafsson, 1997, Thrombosis and Haemostasis.

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat.

S. Carlsson, D. Gustafsson, M. Elg, 1999, Thrombosis research.

Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low Bioavailability.

J. Kihlberg, F. Bergström, G. Grönberg, 2016, Journal of medicinal chemistry.

Effects of Felodipine on Microvascular Resting Tone and Responses to Nerve Stimulation and Perfusion Pressure Reduction in Rabbit Skeletal Muscle

M. Persson, L. Lindbom, D. Gustafsson, 1990, Journal of cardiovascular pharmacology.

931-115 Phase I Studies on Inogatran, a New Selective Thrombin Inhibitor

P. Held, U. Eriksson, D. Gustafsson, 1995 .

Impairment during marked hypotension of the plasma volume control in hemorrhage.

J. Lundvall, D. Gustafsson, 1982, Acta physiologica Scandinavica.

Influences on central hemodynamics in hemorrhage of beta 2-adrenergic vascular control mechanisms.

J. Lundvall, J. Hillman, D. Gustafsson, 1982, Acta physiologica Scandinavica.

Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction.

T. Hedner, L. Hansson, B. Dahlöf, 1990, Journal of hypertension.

Beta-adrenergic control of peripheral vascular resistance during increased sympatho-adrenal activity.

J. Lundvall, D. Gustafsson, 1981, Acta physiologica Scandinavica.

The Role of BDNF in Experimental and Clinical Traumatic Brain Injury

S. Thams, D. Gustafsson, E. Rostami, 2021, International journal of molecular sciences.

Possible benefit of selective beta 2-blockade in orthostatic hypotension a 'model' study in the cat.

J. Lundvall, D. Gustafsson, 1983, Life sciences.

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

Ulf Bredberg, David Gustafsson, U. Bredberg, 2003, European Journal of Clinical Pharmacology.

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.

Christer Mattsson, Michael Wolzt, David Gustafsson, 2003, Journal of the American College of Cardiology.

Diameter and compliance in the male human abdominal aorta: influence of age and aortic aneurysm.

D Bergqvist, T Länne, B. Sonesson, 1992, European journal of vascular surgery.

Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo

G. Bergström, L. M. Hultén, W. Knecht, 2014, Scientific Reports.

Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid.

J. A. Grant, Jonas Boström, A. Thelin, 2013, Journal of medicinal chemistry.

Translational Success Stories: Development of Direct Thrombin Inhibitors

J. Hirsh, J. Eikelboom, J. Weitz, 2012, Circulation research.

The role of sympathetic activity in atherogenesis: Effects of β-blockade

Ann-Margret Östlund-Lindqvist, G. Hansson, K. Pettersson, 1988 .

beta-Adrenergic dilator effects in consecutive vascular sections of skeletal muscle.

J. Lundvall, J. Hillman, D. Gustafsson, 1982, The American journal of physiology.

Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral Ximelagatran

B. Eriksson, M. Karlsson, J. Mandema, 2003, Clinical Pharmacokinetics.

A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.

B. Eriksson, U. Eriksson, L. Frison, 2002, Thrombosis and haemostasis.

Derivation of haemodynamic information from ultrasonic recordings of aortic diameter changes.

G. Gennser, J. Björkman, H. Stale, 1989, Ultrasound in medicine & biology.

Discovery of ximelagatran in an historical perspective.

D. Gustafsson, 2005, Seminars in vascular medicine.

New Model for In Vivo Studies of Pharmacological Interventions With Endogenous Fibrinolysis: Effects of Thrombin Inhibitors

D. Gustafsson, S. Lenfors, 1996, Seminars in thrombosis and hemostasis.

Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo

G. Bergström, L. M. Hultén, W. Knecht, 2014, Scientific Reports.